UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2532-2539

2013

Volltextzugriff (PDF)

Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals

Journal of clinical oncology, 2005-06, Vol.23 (18), p.4192-4197

2005

Volltextzugriff (PDF)

Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?

Cancer imaging, 2022-06, Vol.22 (1), p.26-26, Article 26

2022

Volltextzugriff (PDF)

A review on the added value of whole-body MRI in metastatic lobular breast cancer

European radiology, 2022-09, Vol.32 (9), p.6514-6525

2022

Volltextzugriff (PDF)

Taxanes in the treatment of early breast cancer

Cancer treatment reviews, 2005-12, Vol.31 (8), p.618-627

2005

Volltextzugriff (PDF)

A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer (aBC): Interim results of the ESTHER study (NCT02393924)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13039-e13039

2023

Volltextzugriff (PDF)

Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.514-514

2019

Volltextzugriff (PDF)

Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.512-512

2024

Volltextzugriff (PDF)

ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1009-1009

2022

Volltextzugriff (PDF)

Efficacy and tolerability of first-line anti-HER2 therapy for HER2+ advanced breast cancer: A single-centre real-world experience

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13014-e13014

2018

Volltextzugriff (PDF)

Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1024-1024

2022

Volltextzugriff (PDF)

A Randomized Study of Electronic Diary versus Paper and Pencil Collection of Patient-Reported Outcomes in Patients with Non-Small Cell Lung Cancer

The patient : patient-centered outcomes research, 2008-04, Vol.1 (2), p.105-113

2008

Volltextzugriff (PDF)

Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1041-1041

2019

Volltextzugriff (PDF)

Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1055-1055

2020

Volltextzugriff (PDF)

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA (ctDNA) in metastatic breast cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1015-1015

2017

Volltextzugriff (PDF)

Ongoing needs in 625 women living beyond early breast cancer

Journal of clinical oncology, 2017-02, Vol.35 (5_suppl), p.139-139

2017

Volltextzugriff (PDF)

PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA -mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA -mutant (mt) ER-negative advanced breast cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1051-1051

2019

Volltextzugriff (PDF)

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1056-1056

2018

Volltextzugriff (PDF)

Real-world experience of exemestane-everolimus (EXE-EVE) in elderly patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.576-576

2016

Volltextzugriff (PDF)

Comprehensive geriatric assessment (CGA) in men age 70 or over with localized prostate cancer

Journal of clinical oncology, 2014-02, Vol.32 (4_suppl), p.184-184

2014

Volltextzugriff (PDF)

Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS1617-TPS1617

2014

Volltextzugriff (PDF)

Predictors of response to systemic therapy in breast cancer

Forum (Genoa, Italy), 2002, Vol.12 (1), p.19

2002

Volltextzugriff (PDF)

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer

Annals of oncology, 2018-01, Vol.29 (1), p.145-153

2018

Volltextzugriff (PDF)

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

JAMA oncology, 2019-10, Vol.5 (10), p.1473

2019

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBritish Journal Of Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(46)
Buchkapitel
(2)

Sprache

Englisch
(48)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study

Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals

Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?

A review on the added value of whole-body MRI in metastatic lobular breast cancer

Taxanes in the treatment of early breast cancer

A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer (aBC): Interim results of the ESTHER study (NCT02393924)

Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer

Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial

ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study

Efficacy and tolerability of first-line anti-HER2 therapy for HER2+ advanced breast cancer: A single-centre real-world experience

Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010)

A Randomized Study of Electronic Diary versus Paper and Pencil Collection of Patient-Reported Outcomes in Patients with Non-Small Cell Lung Cancer

Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC)

Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC)

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA (ctDNA) in metastatic breast cancer

Ongoing needs in 625 women living beyond early breast cancer

PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA -mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA -mutant (mt) ER-negative advanced breast cancer

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial

Real-world experience of exemestane-everolimus (EXE-EVE) in elderly patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC)

Comprehensive geriatric assessment (CGA) in men age 70 or over with localized prostate cancer

Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors

Predictors of response to systemic therapy in breast cancer

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

Cost-Effectiveness Modeling of Surgery Plus Adjuvant Endocrine Therapy Versus Primary Endocrine Therapy Alone in UK Women Aged 70 and Over With Early Breast Cancer

Aktive Filter

Suchergebnisse filtern